Related Experiment Video

Updated: Jul 14, 2026

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

Effects of beta blockers on left ventricular diastolic function: the importance of optimal heart rate reduction

Renaldas Jurkevicius1, Gintare Sakalyte, Ausra Kavoliŭniene

  • 1Department of Cardiology, Kaunas University of Medicine, Kaunas, Lithuania.

Acta Cardiologica
|July 5, 2007
PubMed

Insights

Beta blockers improved left ventricular diastolic and long axis function in hypertensive patients. This improvement was linked to a significant reduction in heart rate, enhancing overall cardiac function.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Left ventricular (LV) diastolic dysfunction is a key factor in heart failure associated with hypertensive heart disease.
  • Arterial hypertension significantly impacts cardiac function, particularly diastolic and long axis motion.

Purpose of the Study:

  • To investigate the effects of beta blockers on LV diastolic function and long axis motion.
  • To assess the impact of beta blockers in patients with arterial hypertension.

Main Methods:

  • A 12-week treatment with beta blockers was administered to 60 patients with mild-to-moderate arterial hypertension.
  • Echocardiographic assessments, including Doppler transmitral flow and mitral annulus motion analysis, were performed before and after treatment.

Main Results:

  • Beta blocker therapy increased the transmitral early to late diastolic velocity ratio (P < 0.05).
  • Systolic amplitude of mitral annulus motion also increased (P < 0.05).
  • Improvements in LV diastolic and long axis function correlated with heart rate reduction (57-68 bpm).

Conclusions:

  • Beta blockers can enhance LV diastolic and long axis function in hypertensive patients.
  • Achieving significant heart rate reduction is crucial for these functional improvements.
Abstract

More Related Videos

Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease08:57

Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease

Published on: May 22, 2026

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism11:04

Quantification of Global Diastolic Function by Kinematic Modeling-based Analysis of Transmitral Flow via the Parametrized Diastolic Filling Formalism

Published on: September 1, 2014

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...